HAYWARD, Calif. — Two generic drug makers have settled with a subsidiary of Johnson & Johnson and another company concerning a drug used to treat attention deficit hyperactivity disorder.
Impax Labs and Teva Pharmaceuticals USA had settled a patent infringement suit with Janssen Pharmaceuticals and Alza over Concerta (methylphenidate hydrochloride) extended-release tablets in the 18-mg, 27-mg, 36-mg and 54-mg strengths.
Under the agreement, Impax and Teva will be licensed to sell generic versions of the drug starting July 14, 2013. The two companies are pursuing a strategic alliance agreement with regard to the drug.
Branded and generic versions of Concerta had sales of about $1.2 billion during the 12-month period ended in July, according to Wolters Kluwer Health.